A carregar...
Should minimal residual disease negativity not be the end point of myeloma therapy?
Publisher's Note: This article has a companion Point by Anderson. Publisher's Note: Join in the discussion of these articles at Blood Advances Community Conversations.
Na minha lista:
| Publicado no: | Blood Adv |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5728450/ https://ncbi.nlm.nih.gov/pubmed/29296971 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017000109 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|